AZD5438 in Patients With Advanced Solid Malignancies
Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
Purpose of this study is to assess the safety and tolerability of AZD5438 given orally to
patients with advanced solid malignancies A review of the emerging clinical tolerability and
exposure data from this study in conjunction with preclinical and the available clinical
pharmacodynamic data relating to AZD5438, led to a decision by AstraZeneca that the
development of AZD5438 as a potential anti-cancer agent would be discontinued.